Paper Details

  1. Home
  2. Paper Details

Survival modelling and cost-effectiveness analysis of treatments for newly diagnosed metastatic hormone-sensitive prostate cancer.

Author: BarbierMichaela C, HaileSarah R, MengesDominik, PuhanMilo A, SchwenkglenksMatthias, TomonagaYuki, YebyoHenock G

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

While adding docetaxel or new androgen receptor axis-targeted therapies (ARATs) like abiraterone, apalutamide, or enzalutamide to standard treatment (ADT) has shown benefits for men with metastatic hormone-sensitive prostate cancer (mHSPC), the best treatment approach in terms of cost and effectiveness is unclear, especially given the high cost of ARATs.
Paper Details　
Original Abstract of the Article :
In metastatic hormone-sensitive prostate cancer (mHSPC) treatment, survival benefits have been shown by adding docetaxel or recent androgen receptor axis-targeted therapies (ARATs) abiraterone, apalutamide, or enzalutamide to androgen deprivation therapy (ADT). However, the optimal treatment strateg...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632884/

データ提供：米国国立医学図書館（NLM）

Optimal Treatment for Metastatic Hormone-Sensitive Prostate Cancer: Finding the Right Balance

This study delves into the complex world of metastatic hormone-sensitive prostate cancer (mHSPC) treatment. It examines the effectiveness of different treatment strategies, including androgen deprivation therapy (ADT), docetaxel, and newer androgen receptor axis-targeted therapies (ARATs), such as abiraterone, apalutamide, and enzalutamide. The researchers sought to determine the most cost-effective and beneficial treatment approach for patients with mHSPC, considering the significant cost of ARATs.

Balancing Survival Benefits and Cost-Effectiveness

The study aimed to investigate the survival modeling and cost-effectiveness of various treatments for mHSPC. It found that adding docetaxel or ARATs to ADT could improve survival but also raises the question of finding the most cost-effective approach, especially considering the high cost of ARATs. This research is crucial for optimizing treatment strategies for mHSPC patients, balancing the need for effective treatment with the constraints of healthcare costs.

Navigating the Complex Landscape of Prostate Cancer Treatment

The study emphasizes the complexities of mHSPC treatment, requiring a careful balance of survival benefits, cost-effectiveness, and individual patient needs. This research can help inform decision-making for both clinicians and patients, enabling them to choose the most suitable treatment path. It's like finding the right path through a vast and unforgiving desert, where each step must be carefully considered.

Dr.Camel's Conclusion

This study provides valuable insights into the optimization of treatment for metastatic hormone-sensitive prostate cancer. It highlights the importance of finding a balance between survival benefits and cost-effectiveness, recognizing that the most effective treatment is not always the most expensive. This research is a reminder that finding the best path through the desert of disease requires careful navigation and consideration of all available options.

Date :
  1. Date Completed 2022-11-07
  2. Date Revised 2022-11-08
Further Info :

Pubmed ID

36327294

DOI: Digital Object Identifier

PMC9632884

Related Literature

Article Analysis
・Effective treatment of prostate cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.